Phaseline

Companies › Kivu Bioscience

Kivu Bioscience: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KIVU-305
CEACAM5-directed antibody-drug conjugate
CEACAM5Phase 1Solid TumorsDec 2027
KIVU-107
PTK7-directed antibody-drug conjugate
PTK7Phase 1Advance Solid TumorsMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07545356KIVU-305Phase 1Solid TumorsOncologyDec 2027
NCT07229313KIVU-107Phase 1Advance Solid TumorsOncologyMar 2028

Targets

CEACAM5 (1) PTK7 (1)

Companies with the same targets

Chongqing Precision Biotech Beijing Biotech Merck KGaA A2 Biotherapeutics Roche Bristol-Myers Squibb LaNova Medicines Genmab Harbour BioMed (Guangzhou) Fortvita Biologics (USA)Inc.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.